Notably, only a subset of AR enhancers were co-occupied by p300 in prostate cancer cells, which was deterministic of stronger transcriptional activation, evidenced both by higher accessibility and subsequent recruitment of the Mediator and Pol II complexes. This evidence concerns the gene EP300 and prostate carcinoma.